Inventor · disambiguated record
Maria Gloria Beumont
Also filed as: BEUMONT MARIA GLORIA
1 granted patent·10 pending applications·0 citations·filing 2009–2021
13Inventor score
Files withJANSSEN PHARMACEUTICALS INC6VERTEX PHARMA2ARROWHEAD PHARMACEUTICALS INC1BEUMONT MARIA GLORIA1MCNAIR LINDSAY1
Top patents by PatentIndex Score
11 records- 0154US2021395745A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0250US2018021360A1Combination Therapy Regimen For Treatment Of Selected HCV GenotypesJANSSEN PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0350US2021403908A1Compositions and methods for treatment of hepatitis d virus infectionJANSSEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0450US2018021361A1Combination drug treatment for hepatitis c infectionJANSSEN PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0541US2017319572A1Combination drug treatment for hepatitis c infectionJANSSEN PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0639US2017087174A1Combination therapy regimen for treatment of hcvJANSSEN PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0738US8871812B2Therapeutic regimen comprising PEG-interferon, ribavirin and VX-950 for the treatment of hepatitisVERTEX PHARMA·Filed 2012·Granted Oct 28, 2014·0 cites·26 claims
- 0835US2011165119A1Telaprevir dosing regimenBEUMONT MARIA GLORIA·Filed 2009·Application pending·0 cites
- 0929US2011236351A1Therapeutic Regimen Comprising PEG-Interferon, Ribavirin and VX-950 for the Treatment of HepatitisVERTEX PHARMA·Filed 2011·Application pending·0 cites
- 1027US2016206645A1Combination therapies for treatment of hcvJANSSEN PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1119US2012039850A1HCV Combination Therapies Comprising Pegylated Interferon, Ribavirin and TelaprevirMCNAIR LINDSAY·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maria Gloria Beumont files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →